<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00192517</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP102</org_study_id>
    <nct_id>NCT00192517</nct_id>
  </id_info>
  <brief_title>Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis</brief_title>
  <official_title>A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of MEDI-522, a Humanized Monoclonal Antibody to Integrin Alpha V Beta 3, Administered by Subcutaneous Injection to Adults With Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the effects on disease activity, in the
      absence of systemic psoriasis therapy, of 4 mg/kg MEDI-522 versus placebo administered weekly
      by SC injection for 12 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects achieving at least a 50% or 75% improvement of PASI</measure>
    <time_frame>PASI score at Study Days 28, 56, 77, 91, 107, 137, and 167.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events and serious adverse events</measure>
    <time_frame>through Study Day 167</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MEDI-522</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-522</intervention_name>
    <description>4 mg/kg (for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4 mg/kg(for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Plaque psoriasis involving at least 10% of body surface area (Appendix A)

          -  PASI score greater than 12

          -  Age 18 through 65 years at the time of the first dose of study drug

          -  Both males and females are eligible. However, sexually active females, unless
             surgically sterile or at least 1 year post-menopausal, must have used an effective
             method of avoiding pregnancy (including oral or implanted contraceptives, IUD, female
             condom, diaphragm with spermicide, cervical cap, abstinence, use of a condom by the
             sexual partner or sterile sexual partner) for 30 days prior to the first dose of study
             drug and must agree to continue using such precautions for 60 days after the final
             dose of study drug

          -  Prior to randomization (must be within 21 days of the first administration of the
             study drug), all of the following: WBC less than or equal to 3,800/mm3; hematocrit
             above 32%, platelet count less than or equal to 140,000/mm3; AST, ALT, BUN, or
             creatinine&lt;1.5 x ULN; and stool negative for occult blood

          -  Currently receiving no therapy for psoriasis except emollients

          -  Written informed consent obtained from the patient

          -  Ability to complete follow-up period of 167 days as required by the protocol

        Exclusion Criteria:

          -  Pustular, guttate, or erythrodermic psoriasis as the predominant disease type

          -  Evidence of active hepatitis A, hepatitis B virus (HBV) or hepatitis C virus (HCV)
             infection, such as positive HBsAg or positive anti-hepatitis C antibody

          -  Pregnancy (must have a negative serum pregnancy test within 21 days prior to the first
             dose of study drug, and urine pregnancy test must be negative on Study Day 0 before
             study entry)

          -  History of cancer (except excision of basal cell carcinoma)

          -  Evidence of significant active infection, such as fever less than or greater to 38.0°C
             (100.5°F), or chronic systemic infection

          -  Known or suspected infection with human immunodeficiency virus (HIV) or other evidence
             of clinically significant immune deficiencies

          -  Diagnosis of psoriatic arthritis or rheumatoid arthritis requiring active treatment

          -  History of hematuria due to chronic cystitis, recurrent kidney stones, or nephritis,
             history of CVA, poorly controlled hypertension, angina, stable abdominal aneurysm,
             recent superficial phlebitis, or recent myocardial infarction (within past 1 year
             without definitive corrective surgery such as coronary bypass graft or angioplasty)

          -  Receipt of systemic therapy for psoriasis or immunosuppressive medication in the past
             4 weeks, including systemic retinoids, systemic steroids (oral, IM, or IV),
             cyclosporine A,methotrexate, azathioprine, anti-TNF agents, anti-T-cell agents,
             phototherapy (PUVA, UVB,tanning bed use), coal tar treatment (Goeckerman or modified
             Goeckerman regimen), tacrolimus, or mycophenolate

          -  Use of topical therapy for psoriasis in the past 2 weeks, such as steroid containing
             creams, Vitamin D analog creams and coal tar shampoos

          -  Receipt of any investigational drug therapy within 4 weeks before the first dose of
             study drug in this protocol (use of licensed agents for indications not listed in the
             package insert is permitted)

          -  Current or planned participation in a research protocol in which an investigational
             agent or therapy may be administered

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             MEDI-522

          -  Nursing mother

          -  Evidence of acute illness

          -  Clinical manifestations of significant end organ dysfunction or failure that may
             compromise the safety of the patient in the study

          -  History of gastrointestinal bleeding (i.e., stool positive for occult blood or overt
             bleeding) within the previous 6 months

          -  Known bleeding disorder or significant risk of clinically important abnormal bleeding
             due to anticoagulant therapy with warfarin or heparin

          -  Insulin-dependent diabetes mellitus that is recent-onset or unstable

          -  Elective surgery planned during the study period through Study Day 167
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara White, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bressinck, Gibson, Parker, Dinehart, Sanster Dermatology, PA</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates In Research, Inc.</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Solano Dermatology Associates</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Savin Center, P.C.</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511-4808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Florida Dermatology Associates, P.A.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Dermatology, Vein &amp; Research Center, LLC</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Bend Clinic</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FutureCare Studies, INC</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Cutaneous Research, Corp.</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Dermatology</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karen Harkaway, M.D., LLC</name>
      <address>
        <city>Delran</city>
        <state>New Jersey</state>
        <zip>08075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthEast Clinical Research Centers, Inc</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clincial Partners, LLC</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harmony Clinical Research</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tenn. Clinical Research Center, INC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derm. Clinical Research Center of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Bay Dermatology Center</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 2T6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Probity Medical Research, Inc.</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>April 2, 2009</last_update_submitted>
  <last_update_submitted_qc>April 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Barbara White, M.D.</name_title>
    <organization>MedImmune Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

